Revenues for the first half of 2024 and update on AB Science’s activities
10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities
Read more
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million euros
09/10/2024 – AB Science announces today that it has completed the settlement and delivery of the capital increase announced on September 30, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial report
30/09/2024 – The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024
AB Science announces the success of a 5.0 million euros capital increase
30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros
AB Science provides an update on the microtubule program AB8939
26/09/2024 – AB Science today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
23/09/2024 – AB Science today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference
Positive results of the Phase 2 study evaluating masitinib in Covid-19
08/07/2024 – AB Science today announces the results of a Phase 2 study evaluating masitinib in COVID-19
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
28/06/2024 – AB Science today announces that the CHMP has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of masitinib in the treatment of ALS
June 26, 2024 CGM – Q&A document
26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024 – AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
AB Science webcast of May 30, 2024
30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS
Corrective statement on the consolidated accounts as of December 31, 2023
17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023
Annual financial results as of 31 December, 2023
15/05/2024 – AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patients
07/05/2024 – AB Science today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine
The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
02/05/2024 – AB Science announced today that the Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
AB Science announces a slight delay in the publication of its 2023 annual financial report
30/04/2024 – The Company will publish its annual financial report no later than May 15, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
03/04/2024 – AB Science today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS)
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13/03/2024 – AB Science today announced the publication of new preclinical results for masitinib in neurodegenerative diseases
Summary of the live webcast held on March 4, 2024, providing an update on AB Science development
07/03/2024 – AB Science is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development
Two financial analysis firms initiate coverage of AB Science
06/03/2024 – AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
AB Science webcast of March 4, 2024
04/03/2024 – Presentation of the AB Science webcast held on March 4, 2024
Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
01/03/2024 – AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALS
26/02/2024 – AB Science today announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26/01/2024 – AB Science announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of Outstanding Issues at D195 of the procedure, instead of addressing these issues through the Oral Explanation
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006
AB Science webcast – Masitinib in Sickle Cell Disease
30/11/2023 – Presentation of the Masitinib in Sickle Cell Disease webcast
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell disease
28/11/2023 – AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
27/11/2023 – AB Science announces today that a new clinical development program for masitinib in sickle cell disease is among the 19 winning projects to be funded under the sixth call for “Hospital-University Research in Health” (Recherche Hospitalo-Universitaire en santé) projects, which part of the Future Investments Program
Revenues for the first half of 2023 and update on AB Science’s activities
29/09/2023 – AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
18/09/2023 – AB Science today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) timetable for examination of the masitinib marketing authorization application in amyotrophic lateral sclerosis (ALS)
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
26/06/2023 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from study AB12003
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
01/06/2023 – AB Science today announced that the patent office of Canada has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
AB Science to hold its Annual General Meeting of Shareholders on June 30, 2023
30/05/2023 – AB Science will hold its Annual General Meeting on Friday 30 June 2023 at 3.30pm
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
17/05/2023 – AB Science today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023)
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
09/05/2023 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
Annual financial results as of 31 December, 2022
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27/04/2023 – AB Science today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston, USA
Presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting
Success of the capital increase by private placement for an amount of 15 million euros
24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros
Implementation of a new strategy and launch of a capital increase
21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
18/04/2023 – AB Science today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
12/04/2023 – AB Science today announced that Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm), will deliver a presentation on masitinib in amyotrophic lateral sclerosis (ALS) to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy…
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
04/04/2023 – AB Science today provides an update on the schedule for the evaluation by the European Medicines Agency (EMA) and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
AB Science webcast – Microtubule Destabilizer Agents (MDA) platform
16/03/2023 – Presentation of the AB Science Microtubule Destabilizer Agents platform webcast
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
13/03/2023 – AB Science today announces a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute myeloid leukemia (AML)
Publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer’s Research & Therapy
28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
31/01/2023 – AB Science announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB)
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
29/12/2022 – AB Science announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA)
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS)
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
22/12/2022 – AB Science announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB)
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
21/11/2022 – AB Science today announced that it has received an Investigational New Drug (IND) approval letter from the FDA to initiate Phase III study (AB21004) in patients with mild to moderate Alzheimer’s disease
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
10/10/2022 – AB Science today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer’s Disease
Revenues for the first half of 2022 and update on AB Science’s activities
30/09/2022 – AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
14/09/2022 – AB Science announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
24/08/2022 – AB Science today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS)
Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and Allergy
07/06/2022 – AB Science today announced the publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
26/05/2022 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
Annual financial results as of 31 December, 2021
29/04/2022 – AB Science reports its revenues for the year 2021 and provides an update on its activities
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19
28/04/2022 – AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)
29/03/2022 – AB Science acknowledges the decision of the Enforcement Committee of the French market regulator (AMF), which has cleared its Chief Executive Officer, Alain Moussy, in a decision concerning possible insider trading.
Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
28/02/2022 – Presentation of the webcast held on February 28, 2022 on masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
Financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants
AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
24/02/2022 – AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications
Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
22/02/2022 – AB Science announced the publication of results from its positive pivotal phase 3 trial of masitinib in progressive forms of multiple sclerosis in the peer-reviewed journal Neurology® Neuroimmunology & Neuroinflammation
Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy
21/02/2022 – AB Science today announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy
Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)
12/02/2022 – AB Science wishes to provide clarifications following press articles published after the public hearing of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022
AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit
07/02/2022 – AB Science will deliver a presentation on the Amyotrophic Lateral Sclerosis (ALS) masitinib development program at the 2022 ALS Drug Development Summit
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency
02/02/2022 – AB Science today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)
AB Science granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)
19/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
03/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
29/11/2021 – AB Science today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
22/11/2021 – AB Science today announces that its Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML and refractory myelodysplastic syndrome (MDS) has received Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA)
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
18/11/2021 – AB Science today announced that it has received authorization from the United States Food and Drug Administration (FDA) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with amyotrophic lateral sclerosis (ALS)
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
18/10/2021 – AB Science announced that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
04/10/2021 – AB Science today announced that its clinical development program of masitinib in adult patients with mast cell activation syndrome (MCAS) has been approved by the U.S. Food and Drug Administration (FDA)
Revenues for the first half of 2021 and update on AB Science’s activities
30/09/2021 – AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
28/09/2021 – AB Science today announced that a new clinical trial with masitinib in patients with symptomatic mild and moderate COVID-19 has been approved by the Regulatory Authorities of Russia and South Africa
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia
22/09/2021 – AB Science today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada
Abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
20/09/2021 – AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
Authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19
16/09/2021 – AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
New authorizations to resume patient enrollment in Phase 3 studies of masitinib
14/09/2021 – AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
Results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
13/09/2021 – AB Science today announced that results from masitinib study AB12003 in metastatic castrate refractory prostate cancer, have been presented as a podium presentation at the 2021 American Urological Association
Latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
02/09/2021 – AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
Second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis
25/08/2021 – AB Science announced today that it has received authorization from the French National Agency (ANSM) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB15003) in mastocytosis
First authorization to resume patient enrollment in the Phase 3 study of masitinib in ALS
23/08/2021 – AB Science today announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in amyotrophic lateral sclerosis (ALS)
Publication of a pathogenic mechanism triggered by mast cells in the ALS spinal cord that can be targeted by masitinib
19/08/2021 – AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
Q&A press release following-up on the June 28, 2021 press release relating to an agreement with historical shareholders
06/08/2021 – AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
Results from Phase 3 AB09004 study on Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)
29/07/2021 – AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)
Presentation of results from Phase 3 AB09004 study on Alzheimer’s disease at the annual Alzheimer’s Association International Conference (AAIC)
22/07/2021 – AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
Publication in the world-renowned journal Science confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
20/07/2021 – AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
Publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
19/07/2021 – AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
Validation of the Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France
12/07/2021 – AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France
Results of the Combined General Shareholders’ Meeting of June 30, 2021
01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021
Signature of an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
28/06/2021 – AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
Results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
10/06/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
Summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
08/06/2021 – AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
Webcast presentation following the voluntary hold of clinical studies with masitinib
08/06/2021 : Presentation of the webcast that was held following the voluntary hold of clinical studies with masitinib
Live webcast on Thursday June 3, 2021 following the voluntary hold in the clinical studies of masitinib
02/06/2021 – AB Science will host a live webcast on June 3, 2021 to provide details on the decision to suspend voluntarily the clinical studies with masitinib
AB Science announces a voluntary hold in the clinical studies of masitinib
01/06/2021 – AB Science announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide
Results from Phase 3 study evaluating masitinib in prostate cancer
26/05/2021 – AB Science communicated the results from Phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021
Masitinib in Prostate Cancer Webcast Presentation
25/05/2021 – Presentation of the webcast held on May 25, 2021 on masitinib in prostate Cancer Download PDF
Live webcast on Tuesday May 25, 2021 on masitinib’s results in prostate cancer
21/05/2021 – AB Science will host a live webcast on May 25, 2021 to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer
Results from masitinib study AB12005 in pancreatic cancer selected for presentation at the ASCO Annual Meeting
20/05/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
Annual financial results as of 31 December, 2020
30/04/2021 – AB Science reports its annual financial results as of 31 December, 2020
Masitinib Phase 2B/3 study in prostate cancer met its primary endpoint
29/04/2021 – AB Science today announces that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans
Signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
06/04/2021 – AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
Update on masitinib Phase 3 study in prostate cancer
31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
A new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders
08/03/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer’s Disease
A new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
23/02/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
A new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro
25/01/2021 – AB Science announces that a new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19
Boursorama interview of Alain Moussy, CEO of AB Science
23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama
Capital raise for a total amount of 15 million euros
21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros
Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
Masitinib in Alzheimer’s Disease Webcast Presentation
17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease
Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020
17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020
Corrective press release regarding adverse events information from study AB09004
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s Disease
16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
Positive Phase 2/3 study AB09004 with masitinib in Alzheimer’s Disease
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer
Positive confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain
04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival
Signature of a 15.0 million financing deal with the European Investment Bank
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
Positive top-line Phase 3 results for oral masitinib in severe asthma
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium
13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020
First half of 2020 results
30/09/2020 – AB Science reports its revenues for the first half of 2020
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference
AB Science to present results from its AB07015 study in severe asthma at the annual European Respiratory Society International Congress
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
AB Science to present results from its AB07002 study in progressive forms of MS at MSVirtual2020
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19
Results of the Combined General Shareholders’ Meeting of August 31, 2020
01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020
New results published in Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
08/07/2020 – AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual Congress
10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress
Postponement of AB Science Annual General Shareholders’ meeting
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020
07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020
Presentation of the results from the Phase 3 AB07015 study in severe asthma at the EAACI 2020 Annual Congress
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress
Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
Annual financial results as of 31 December, 2019
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
Letter to our stakeholders on COVID-19 pandemic impact on AB Science studies
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
FDA clears masitinib IND in Amyotrophic Lateral Sclerosis, allowing U.S. patient enrollment to commence in Phase 3 study
31/03/2020 – AB Science today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the Company to initiate its masitinib Phase 3 study (AB19001) in amyotrophic lateral sclerosis
Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 results in Progressive Forms of MS
09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis
New fundraising of EUR 12.3 million
02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million
Positive top-line Phase 2B/3 results for masitinib in progressive forms of MS
20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancer
08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
Webcast on masitinib in severe asthma on Monday, December 2, 2019
27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis
25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
Positive top-line Phase 3 results for masitinib in severe asthma
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
Financing agreement to pre-finance the 2019 research tax credit
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
Webcast on indolent systemic mastocytosis on November 20, 2019
04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019
Authorization to initiate phase 3 confirmatory study in mastocytosis
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
Update on masitinib programs timelines
10/10/2019 – AB Science provides update on masitinib programs timelines
First half of 2019 results
30/09/2019 – AB Science reports its revenues for the first half of 2019
10M€ raised through a private placement
19/08/2019 – AB Science announces the success of a private placement
AB Science to present at two upcoming conferences in September 2019
12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
Update on masitinib clinical program
05/08/2019 – AB Science provides an update on its masitinib clinical program.
Results of masitinib study in metastatic melanoma
02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.
AB Science Corporate Presentation
22/07/2019 – AB Science Corporate Presentation – July 2019
Summary of the webconference held on July 8, 2019
09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019
July 8 2019 web conference presentation
08/07/2019 – AB Science web conference presentation
Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal ALSFD
08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure
04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
Results of interim analysis for masitinib in Alzheimer’s Disease
26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease
June 14 2019 web conference presentation
14/06/2019 – AB Science web conference presentation
Positive IDMC recommendation following interim analysis in pancreatic cancer
12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer
Upcoming news flow
10/06/2019 – AB Science is providing the upcoming news flow of the Company
Updated corporate overview
10/06/2019 – AB Science is providing an updated coporate overview of the Company
Summary of the webconference held on June 5, 2019
05/06/2019 – AB Science is providing a summary of the web conference held on 5 June, 2019
Summary of the webconference held on June 4, 2019
04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019
June 4 2019 web conference presentation
04/06/2019 – AB Science web conference presentation (Part 1)
Web conference on June 4 and 5, 2019
30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
Lifting of the ANSM clinical hold
28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.
Annual financial results as of 31 December, 2018
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.